| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jin Hee Park | |
| Na Kyung Lee | |||
| Soo Young Lee | |||
| P2860 | cites work | The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway | Q22009096 |
| The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis | Q24297505 | ||
| Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1 | Q24300916 | ||
| Distinct molecular mechanism for initiating TRAF6 signalling | Q24302174 | ||
| Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell-cell fusion | Q24322030 | ||
| Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 | Q24537518 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Impaired differentiation of osteoclasts in TREM-2-deficient individuals | Q24672735 | ||
| A novel member of the leukocyte receptor complex regulates osteoclast differentiation | Q24675157 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| Skeletal remodeling in health and disease | Q28235713 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase | Q28278061 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption | Q28592760 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Missing pieces in the NF-kappaB puzzle | Q29547864 | ||
| Genetic regulation of osteoclast development and function | Q29617421 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Transcriptional regulation by calcium, calcineurin, and NFAT | Q29620410 | ||
| NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism | Q30157499 | ||
| The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors | Q30358458 | ||
| NFAT and Osterix cooperatively regulate bone formation | Q31813054 | ||
| Blimp1-mediated repression of negative regulators is required for osteoclast differentiation | Q33733731 | ||
| The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. | Q33794960 | ||
| Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis | Q34369482 | ||
| PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β. | Q34424327 | ||
| Reaching a genetic and molecular understanding of skeletal development | Q34611297 | ||
| Functions of AP1 (Fos/Jun) in bone development | Q34963037 | ||
| The TNF receptor superfamily: role in immune inflammation and bone formation | Q35176348 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Erk1 positively regulates osteoclast differentiation and bone resorptive activity | Q35227805 | ||
| Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation | Q35604256 | ||
| Capacitative calcium entry: sensing the calcium stores | Q36113705 | ||
| The molecular understanding of osteoclast differentiation | Q36650749 | ||
| Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis | Q36739991 | ||
| Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation | Q36910760 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice | Q37143375 | ||
| Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation | Q37286240 | ||
| NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). | Q37302319 | ||
| Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis | Q37370702 | ||
| How are osteoclasts induced to resorb bone? | Q37968673 | ||
| Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade | Q38467858 | ||
| PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. | Q38744013 | ||
| Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | Q39714931 | ||
| Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. | Q40701095 | ||
| Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts | Q42762796 | ||
| Autoamplification of NFATc1 expression determines its essential role in bone homeostasis | Q42972503 | ||
| p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function | Q44072080 | ||
| TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function | Q44912776 | ||
| Vav3 regulates osteoclast function and bone mass | Q45265424 | ||
| A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation | Q46427712 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. | Q51040187 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. | Q53364532 | ||
| Induction of DC-STAMP by Alternative Activation and Downstream Signaling Mechanisms | Q57675118 | ||
| NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 | Q57675122 | ||
| JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms | Q58326878 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| Bone and haematopoietic defects in mice lacking c-fos | Q58326969 | ||
| MafB negatively regulates RANKL-mediated osteoclast differentiation | Q79421924 | ||
| P433 | issue | 10 | |
| P921 | main subject | cell | Q7868 |
| cell differentiation | Q210861 | ||
| membrane protein | Q423042 | ||
| cell surface receptor | Q2476074 | ||
| P304 | page(s) | 706-713 | |
| P577 | publication date | 2017-10-01 | |
| 2017-10-17 | |||
| P1433 | published in | Molecules and Cells | Q12623193 |
| P1476 | title | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation | |
| P478 | volume | 40 |
| Q64329499 | A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity |
| Q91891005 | Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis |
| Q97421408 | An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision |
| Q90622984 | Angiogenesis stimulated by elevated PDGF-BB in subchondral bone contributes to osteoarthritis development |
| Q98177435 | Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways |
| Q57490079 | Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption |
| Q94673370 | Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy |
| Q92703962 | Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-κB Ligand (RANKL) |
| Q92422244 | Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression |
| Q92257336 | Fermented Sea Tangle (Laminaria japonica Aresch) Suppresses RANKL-Induced Osteoclastogenesis by Scavenging ROS in RAW 264.7 Cells |
| Q90412365 | Ferryl Hemoglobin Inhibits Osteoclastic Differentiation of Macrophages in Hemorrhaged Atherosclerotic Plaques |
| Q90451142 | Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health |
| Q64234995 | Gene co-expression network analysis identifies BRCC3 as a key regulator in osteogenic differentiation of osteoblasts through a β-catenin signaling dependent pathway |
| Q99414171 | Heterogeneity and Actin Cytoskeleton in Osteoclast and Macrophage Multinucleation |
| Q90290403 | Hexane Fraction of Turbo brunneus Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss |
| Q91606550 | Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway |
| Q64085314 | Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function |
| Q90474952 | Isosteviol Derivative Inhibits Osteoclast Differentiation and Ameliorates Ovariectomy-Induced Osteoporosis |
| Q59813634 | Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis |
| Q64374829 | KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy |
| Q89977149 | METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export |
| Q92000747 | Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro |
| Q64120770 | MicroRNAs: Key Regulators to Understand Osteoclast Differentiation? |
| Q91700438 | Myeloid-Derived Suppressor Cells at the Intersection of Inflammaging and Bone Fragility |
| Q90182318 | Nrf2 is required for suppressing osteoclast RANKL-induced differentiation in RAW 264.7 cells via inactivating cannabinoid receptor type 2 with AM630 |
| Q89998406 | Osthole-loaded N-octyl-O-sulfonyl chitosan micelles (NSC-OST) inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in rats |
| Q90192899 | PSTP-3,5-Me Inhibits Osteoclast Differentiation and Bone Resorption |
| Q91726950 | Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment |
| Q64065836 | Protective Effects of Fermented Oyster Extract against RANKL-Induced Osteoclastogenesis through Scavenging ROS Generation in RAW 264.7 Cells |
| Q94550612 | QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism |
| Q92126865 | Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases |
| Q90599364 | Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by attenuating osteolytic destruction and CAF formation |
| Q90567814 | Role of APD-Ribosylation in Bone Health and Disease |
| Q59790947 | Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals |
| Q93006830 | TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression |
| Q64883900 | TRAF6 Distinctly Regulates Hematopoietic Stem and Progenitors at Different Periods of Development in Mice. |
| Q64273743 | Tetrandrine enhances the ubiquitination and degradation of Syk through an AhR-c-src-c-Cbl pathway and consequently inhibits osteoclastogenesis and bone destruction in arthritis |
| Q92132109 | The Skeletal-Protecting Action and Mechanisms of Action for Mood-Stabilizing Drug Lithium Chloride: Current Evidence and Future Potential Research Areas |
| Q89456517 | The application of nanogenerators and piezoelectricity in osteogenesis |
| Q54978667 | Ubiquitin-dependent proteolysis of CXCL7 leads to posterior longitudinal ligament ossification. |
Search more.